ライフサイエンスコーパス: 5-hydroxytryptophan

1 ted by biogenic amine precursors (L-DOPA and 5-hydroxytryptophan).

2 o produce 5-HT from its immediate precursor, 5-hydroxytryptophan.

3 ke up and metabolize the serotonin precursor 5-hydroxytryptophan.

4 ith further improvement with the addition of 5-hydroxytryptophan.

5 rin-dependent hydroxylation of tryptophan to 5-hydroxytryptophan.

6 of molecular oxygen into tryptophan to form 5-hydroxytryptophan.

7 e precursor levodopa and serotonin precursor 5-hydroxytryptophan.

8 onths after T1D diagnosis (n = 16), by (11)C-5-hydroxytryptophan ((11)C-5-HTP) positron emission tomo

9 tron emission tomography (PET) marker [(11)C]5-hydroxytryptophan ([(11)C]5-HTP) for this purpose.

10 in fVAS was similar in placebo- (37.6%) and 5-hydroxytryptophan (35.6%)-treated patients (P = .830).

11 s, adjunct treatment with the 5-HT precursor 5-hydroxytryptophan (5-HTP) elevates 5-HTExt beyond the

12 5-hydroxytryptophan (5-HTP) has shown therapeutic promis

13 (1) determination ex vivo of accumulation of 5-hydroxytryptophan (5-HTP) in tissue from the dorsal an

14 Accumulation of 5-hydroxytryptophan (5-HTP) in vivo, in the presence of

15 cted, treatment with the serotonin precursor 5-hydroxytryptophan (5-HTP) increased the intensity of s

16 tions of serotonin with the direct precursor 5-hydroxytryptophan (5-HTP) would modulate the ability o

17 ribution of the immediate precursor of 5-HT, 5-hydroxytryptophan (5-HTP), in two model opisthobranch

18 ated during lactation and after injection of 5-hydroxytryptophan (5-HTP).

19 emented with saline (CON, 8 mL/day n = 4) or 5-hydroxytryptophan (5-HTP, 90 mg/day, n = 4) for 10 con

20 Following oxidation of 5-hydroxytryptophan (5-HTPP) at a pyrolytic graphite ele

21 A pair to insert the noncanonical amino acid 5-hydroxytryptophan (5-OHTrp) at position 72 in recombin

22 Central serotonin (5-hydroxytryptophan, 5-HT) modulates somatosensory trans

23 hemically promoted coupling reaction between 5-hydroxytryptophan (5HTP) and simple aromatic amines-el

24 id azo-coupling reaction (CRACR) directed to 5-hydroxytryptophan (5HTP) is compatible with strain-pro

25 ive by itself, was then combined either with 5-hydroxytryptophan (5HTP), a serotonin precursor, or wi

26 The concentrations of 5HT and 5-hydroxytryptophan (5HTP, an index of 5HT synthesis) we

27 further show that 7-azatryptophan (7AW) and 5-hydroxytryptophan (5HW) can also serve as a FRET accep

28 tryptophan analogues, 7-azatryptophan (7AW), 5-hydroxytryptophan (5HW), and 4-, 5-, and 6-fluorotrypt

29 The set of tryptophan analogues includes 5-hydroxytryptophan, 7-azatryptophan, 4-fluorotryptophan

30 The tryptophan analogues, 5-hydroxytryptophan, 7-azatryptophan, 4-fluorotryptophan

31 Tyrosine and the serotonin-precursor 5-hydroxytryptophan also activate AHR signaling in combi

32 1P) antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide, and by 1.0 microM tropisetron

33 5-Hydroxytryptophan and 7-azatryptophan have red-shifted

34 3.73; P = .660) were both comparable between 5-hydroxytryptophan and placebo treatment as well as cha

35 Despite a significant increase in serum 5-hydroxytryptophan and serotonin levels, oral 5-hydroxy

36 els of 5-HT, its precursors L-tryptophan and 5-hydroxytryptophan and the metabolite 5-hydroxyindole a

37 roxyindoles serotonin (5-hydroxytryptamine), 5-hydroxytryptophan, and 5-hydroxyindole acetic acid are

38 ired for the synthesis of physostigmine from 5-hydroxytryptophan, as shown by in vitro total reconsti

39 lectively monitors the fluorescence yield of 5-hydroxytryptophan by exciting the reaction mix at 300

40 rs, such as l-(11)C-methionine and l-1-(11)C-5-hydroxytryptophan, demonstrated promising results, inc

41 hydroxytryptophan and serotonin levels, oral 5-hydroxytryptophan did not modulate IBD-related fatigue

42 The unfolding data show that 5-hydroxytryptophan does not perturb the stability of wi

43 rm-Raman spectroscopy proves the presence of 5-hydroxytryptophan, epidermal TPH activity is completel

44 n treatment, a significant increase in serum 5-hydroxytryptophan (estimated mean difference, 52.66 ng

45 Chemical-quench analyses show that 5-hydroxytryptophan forms with a rate constant of 1.3 s(

46 etically encoded the noncanonical amino acid 5-hydroxytryptophan in both E. coli and eukaryotes, enab

47 droxyphenylalanine, N'-formylkynurenine, and 5-hydroxytryptophan in the nmol/mol-mmol/mol amino acid

48 t spectral characteristics of tryptophan and 5-hydroxytryptophan is presented.

49 er an initial increase in the 5-HT precursor 5-hydroxytryptophan it too decreased with increasing amm

50 of the purified fusion enzyme is 80 nmol of 5-hydroxytryptophan/min/mg.

51 r, the occurrence of four indolic compounds (5-hydroxytryptophan, N-acetylserotonin, 3-indoleacetic a

52 eated in a crossover manner with 100 mg oral 5-hydroxytryptophan or placebo twice daily for 2 consecu

53 f Cbln2 KO mice with the serotonin precursor 5-hydroxytryptophan or the serotonin reuptake-inhibitor

54 reagents onto a site-specifically installed 5-hydroxytryptophan residue (5HTP) on full-length protei

55 The 5-hydroxytryptophan residue was shown to allow rapid, ch

56 alanine and tryptophan, forming tyrosine and 5-hydroxytryptophan, respectively.

57 oxindolylalanine, hydroxypyrroloindole, and 5-hydroxytryptophan result in characteristic chemical sh

58 Supplementing milk replacer with 5-hydroxytryptophan (serotonin precursor) or fluoxetine

59 ons and fatigue, we determined the effect of 5-hydroxytryptophan supplementation on fatigue in patien

60 precursor of dopamine), and tryptophan into 5-hydroxytryptophan (the precursor of serotonin), respec

61 During 5-hydroxytryptophan treatment, a significant increase in

62 yindole acetic acid, but not L-tryptophan or 5-hydroxytryptophan, were reduced in the medulla by 45 a

63 mbiguously distinguish oxindolylalanine from 5-hydroxytryptophan, which are undistinguishable by MS d